sar425899 sanofi dual agonist glp-1 glucagon Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity Gut hormone-based pharmacology: novel formulations

Find pharmacy-related safety alerts, drug recall and new generic drug announcements and other medication information for healthcare providers.

95% CI 0.89, 0.96) and all-cause mortality rate (HR 0.70

Counting the days since you had your last poop? Oof

Whether it is TIDM or TIIDM, if patients do not treat their hyperglycemia through appropriate medical interventions, they may face a series of severe consequences like blindness, kidney failure, or amputation.

Glucagon-like peptide-1 receptor agonists, namely GLP-1 receptor agonists, are a class of drugs for the treatment of type 2 diabetes.

Neurodegenerative diseases, including Alzheimers Disease (AD) and Parkinsons Disease (PD) are common complications of diabetes, arising from insulin resistance, inflammation, and other pathological processes in the central nervous system